Amneal targets biosimilar growth as its core business accelerates
- Q2 2026 revenue grew 10% to $796 million, prompting a second consecutive guidance raise.
- The pending Kashiv deal adds over 20 biosimilar programs and a new long-term growth pillar.
- Specialty revenue rose 17% in Q2, driven by continued strong momentum for CREXONT.
- The stock price already expects better execution, so valuation remains a hurdle for investors.
- Debt will rise after the deal, with net leverage expected around 3.7 times adjusted EBITDA.
A multi-engine growth story
Amneal has moved from a mostly generic drug story to a broader medicine platform. The key change is its pending acquisition of Kashiv BioSciences. That deal adds a full biosimilar engine, from research and manufacturing to selling the drugs in a market targeting more than $100 billion of U.S. opportunity.
The bull case is now about four engines working at once. These are complex Affordable Medicines, CREXONT in Specialty, the Pfizer GLP-1 partnership, and the Kashiv biosimilar pipeline. The near-term numbers back this up. In Q2 2026, total revenue grew 10% to $796 million. The core Affordable Medicines segment accelerated to 13% growth, and the company raised its 2026 revenue and adjusted EBITDA guidance again.
The bear case revolves around execution and debt. The Kashiv deal will push leverage up, and biosimilar price pressure can be harsh. Meanwhile, a recent flood at a Gujarat facility added a $20 million setback on top of an existing, unresolved FDA warning letter. The market already prices Amneal for better execution, resulting in a low valuation score on Finn.
Three reported lines, one new pillar
Amneal reports three segments. Affordable Medicines is the largest. It develops, makes, and sells generic drugs, with a focus on harder products like injectables and inhaled medicines, where fewer rivals can compete.
Specialty sells branded drugs, mainly for brain and hormone-related diseases. This segment is smaller, but it matters because products like CREXONT carry better margins than plain generics if doctors keep adopting them.
AvKARE distributes drugs, over-the-counter products, and medical supplies, mainly to U.S. government buyers. Amneal is intentionally moving this business away from lower-margin distribution sales, which lowers revenue but lifts overall margins.
The pending Kashiv acquisition makes biosimilars a core growth pillar. A biosimilar is a near-copy of a complex biologic drug after the original drug loses protection. These products can be large opportunities, but they require clinical, regulatory, and pricing execution over many years.
What Amneal sells
Affordable Medicines
This is Amneal's largest business, with about 280 product families. It focuses on complex generics with higher barriers to entry.
CREXONT
CREXONT is a Parkinson's disease drug and the main growth driver in Specialty. Its strong launch has fueled recent segment growth.
RYTARY and UNITHROID
RYTARY for Parkinson's disease and UNITHROID for hypothyroidism are key branded products. RYTARY faces generic erosion risk, while UNITHROID adds steady growth.
AvKARE government channel
AvKARE supplies pharmaceuticals and medical products, mainly tied to government channels. Amneal is shifting the mix away from lower-margin distribution work.
Biosimilars and Kashiv pipeline
The pending Kashiv deal adds more than 20 biosimilar programs. Near-term attention is on the XOLAIR biosimilar application, with later programs aimed at ORENCIA, CIMZIA, KEYTRUDA, and OPDIVO.
Pfizer GLP-1 partnership
Amneal is a preferred global supplier and licensed commercial partner in select emerging markets for a GLP-1 portfolio tied to Pfizer. This is a long-term option.
Q2 2026 revenue mix
Segment mix is based on Q2 2026 net revenue of $796 million. Affordable Medicines contributed $490 million, Specialty $149 million, and AvKARE $157 million.
What could go wrong
Kashiv integration misses
High impact · Medium oddsThe Kashiv deal changes Amneal's risk profile. Amneal must combine Kashiv's research and manufacturing with its own commercial system. A slow close, poor handoff, or missed development timeline would hurt the main new growth story.
Gujarat facility issues compound
High impact · Medium oddsThe FDA warning letter for Amneal's Gujarat facility remains a key operating risk. Recent severe flooding caused a $20 million negative impact and temporary shutdown. A slow regulatory fix could affect supply, inspections, or product approvals tied to the site.
Higher debt limits room to move
High impact · Medium oddsThe Kashiv acquisition is expected to lift net leverage to 3.7 times adjusted EBITDA. If EBITDA misses or launch costs rise, debt could limit buybacks, deals, or spending on new products.
Biosimilar price pressure
Medium impact · High oddsBiosimilars can be large markets, but they also attract strong competitors. If several rivals launch near the same time, payers can demand steep discounts. That could make the Kashiv pipeline less profitable than the headline market size suggests.
In one breath
What does Amneal Pharmaceuticals do?
Amneal makes and sells affordable generic medicines, branded specialty drugs, and products for government channels. It is also building a larger biosimilar business through the planned Kashiv acquisition.
Why is the Kashiv deal important for AMRX?
Kashiv gives Amneal a deeper biosimilar pipeline and more control over research, manufacturing, and selling. Management says the combined portfolio targets more than $100 billion of U.S. opportunity.
What is CREXONT?
CREXONT is a branded Parkinson's disease medicine. It is a vital product because its strong uptake is driving the Specialty segment's recent growth.
What should AMRX investors watch next?
The main items are the Kashiv deal closing, quarterly sales of CREXONT, progress on the Gujarat facility warning letter, and FDA action on the XOLAIR biosimilar application.
